Renovare Therapeutics, Inc. Launches From Stealth Mode And Partners With University Of Colorado Boulder To Advance Osteoarthritis Therapies With ARPA-H Funding

Renovare Therapeutics, Inc. Renovare Therapeutics, Inc., a privately held biotechnology company focused on regenerative therapeutics for osteoarthritis, announced its formal launch from stealth mode and the establishment of a collaboration with the University of Colorado University of Colorado Boulder, which received a contract of up to $33.5 million in 2024 from the Advanced Research Projects Agency for Health (ARPA-H) ARPA-H. 

The University recently advanced into the second phase of the award. This non-dilutive funding, provided under ARPA-H’s Novel Innovations for Tissue Regeneration in Osteoarthritis (NITRO) program, will support the continued development of Renovare’s lead product candidates through IND-enabling studies and initial Phase 1 human safety trials. Renovare will work closely with CU Boulder to advance these therapies and other novel products toward commercialization.

The ARPA-H NITRO program is designed to accelerate the development of breakthrough therapies that restore joint function and improve quality of life for the more than 32 million Americans affected by osteoarthritis. The program is led by ARPA-H Program Manager Dr. Ross Uhrich, and in March 2024, it awarded up to $33.5 million over five years to a multi-institutional team from CU Boulder, CU Anschutz, and Colorado State University (CSU). The funding aims to support the creation of minimally invasive therapeutics capable of fully regenerating damaged joints. Over the past two years, the research team has completed extensive nonclinical development on several innovative products, building on core technological advances.

Founded in early 2026, Renovare Therapeutics was created to further develop and commercialize product candidates emerging from the NITRO program. These candidates represent novel approaches to treating osteoarthritis, a degenerative joint disease characterized by the progressive loss of cartilage and bone tissue, resulting in chronic pain, impaired mobility, and reduced quality of life. Unlike current therapies that primarily manage symptoms, Renovare’s regenerative products are designed to halt and potentially reverse disease progression, helping patients regain mobility and return to active lifestyles.

Dr. Stephanie Bryant Dr. Stephanie Bryant, lead Principal Investigator on the NITRO award and Chief Scientific Officer and founder of Renovare Therapeutics, commented that the ARPA-H award represents a significant milestone for the company and for the future of osteoarthritis care. She expressed gratitude for ARPA-H’s support and confidence in the team’s vision to create transformative therapies. Dr. Bryant also highlighted that after years of academic research developing these technologies, it is exciting to see them progress toward clinical evaluation, with the potential to make a meaningful difference in the lives of patients.